{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:34:03Z","timestamp":1770885243367,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalimaging.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Imaging"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clinimag.2022.08.021","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T22:59:12Z","timestamp":1662159552000},"page":"126-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Safety profile of Gadoterate meglumine on the renal function of patients with severe kidney disease"],"prefix":"10.1016","volume":"91","author":[{"given":"Anugayathri","family":"Jawahar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jad","family":"El-Bulbul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clinimag.2022.08.021_bb0005","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1007\/s00330-006-0495-8","article-title":"Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide","volume":"16","author":"Thomsen","year":"2006","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clinimag.2022.08.021_bb0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0741-5214(03)00315-X","article-title":"Safety of gadolinium contrast angiography in patients with chronic renal insufficiency","volume":"38","author":"Sam","year":"2003","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.clinimag.2022.08.021_bb0015","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1681\/ASN.2006060601","article-title":"Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging","volume":"17","author":"Marckmann","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.clinimag.2022.08.021_bb0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2215\/CJN.06011108","article-title":"Current status of gadolinium toxicity in patients with kidney disease","volume":"4","author":"Parazella","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.clinimag.2022.08.021_bb0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejrad.2008.11.021","article-title":"Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study","volume":"73","author":"Janus","year":"2010","journal-title":"Eur Journal Radiol."},{"key":"10.1016\/j.clinimag.2022.08.021_bb0030","series-title":"ACR Manual on Contrast Media, Version 9","year":"2013"},{"key":"10.1016\/j.clinimag.2022.08.021_bb0035","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1007\/s00330-008-0977-y","article-title":"Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions","volume":"18","author":"Sieber","year":"2008","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clinimag.2022.08.021_bb0040","unstructured":"ACR manual on contrast media 2020 by the ACR Committee on drugs and contrast media."},{"issue":"9","key":"10.1016\/j.clinimag.2022.08.021_bb0045","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/RLI.0000000000000462","article-title":"10 years of nephrogenic systemic fibrosis. A comprehensive analysis of nephrogenic systemic fibrosis reports received by a pharmaceutical company from 2006 to 2016","volume":"53","author":"Endrikat","year":"2018","journal-title":"Invest Radiol"},{"key":"10.1016\/j.clinimag.2022.08.021_bb0050","series-title":"Bloomington, IN: Guerbet LLC","year":"2013"},{"issue":"4","key":"10.1016\/j.clinimag.2022.08.021_bb0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10534-008-9135-x","article-title":"Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review","volume":"21","author":"Port","year":"2008","journal-title":"Biometals"},{"issue":"3","key":"10.1016\/j.clinimag.2022.08.021_bb0060","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/cmmi.100","article-title":"Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents","volume":"1","author":"Laurent","year":"2006","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.clinimag.2022.08.021_bb0065","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s00330-012-2705-x","article-title":"Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)","volume":"23","author":"Deray","year":"2013","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1016\/j.clinimag.2022.08.021_bb0070","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ejrad.2011.04.022","article-title":"Tolerability and diagnostic value of gadoterate acid in the general population and in patients with risk factors; results in more than 84,000 patients","volume":"81","author":"Maurer","year":"2012","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.clinimag.2022.08.021_bb0075","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/01.rli.0000248893.01067.e5","article-title":"Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA)","volume":"42","author":"Herborn","year":"2007","journal-title":"Invest Radiol"},{"key":"10.1016\/j.clinimag.2022.08.021_bb0080","unstructured":"http:\/\/www.guerbet-us.com\/products\/contrast-media\/dotaremr-gadoterate-meglumine-injection.html (Accessed on March 30, 2020)."},{"issue":"2","key":"10.1016\/j.clinimag.2022.08.021_bb0085","first-page":"109","article-title":"Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents. The prospective fibrose nephrogenique systemique study","volume":"49","author":"Amet","year":"2014","journal-title":"InvestRadiology"},{"issue":"2","key":"10.1016\/j.clinimag.2022.08.021_bb0090","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jmri.26851","article-title":"Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study","volume":"51","author":"McWilliams","year":"2020","journal-title":"J Magn Reson Imaging"},{"issue":"5","key":"10.1016\/j.clinimag.2022.08.021_bb0095","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2215\/CJN.05371008","article-title":"Estimating glomerular filtration rate: cockcroft-gault and modification of diet in renal disease formulas compared to renal inulin clearance","volume":"4","author":"Botev","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.clinimag.2022.08.021_bb0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/157488608783333989","article-title":"Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis","volume":"3","author":"Perazella","year":"2008","journal-title":"Curr Drug Saf"},{"issue":"8","key":"10.1016\/j.clinimag.2022.08.021_bb0105","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3109\/0886022X.2011.599911","article-title":"Risk of acute kidney injury after exposure to gadolinium-based contrast in patients with renal impairment","volume":"33","author":"Chien","year":"2011","journal-title":"Ren Fail"},{"issue":"10","key":"10.1016\/j.clinimag.2022.08.021_bb0110","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1007\/s00330-002-1628-3","article-title":"Contrast media safety Committee of the European Society of urogenital radiology (ESUR). Gadolinium-containing contrast media for radiographic examinations: a position paper","volume":"12","author":"Thomsen","year":"2002","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clinimag.2022.08.021_bb0115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5414\/CNP75251","article-title":"Rapid deterioration of renal insufficiency after magnetic resonance imaging with gadolinium-based contrast agent","volume":"75","author":"Fujisaki","year":"2011","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.clinimag.2022.08.021_bb0120","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.5858\/2006-130-1354-AGCMNA","article-title":"Are gadolinium-based contrast media nephrotoxic? A renal biopsy study","volume":"130","author":"Akgun","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clinimag.2022.08.021_bb0125","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/RLI.0000000000000307","article-title":"Gadobutrol in renally impaired patients results of the GRIP study","volume":"52","author":"Michaely","year":"2017","journal-title":"Invest Radiol"},{"key":"10.1016\/j.clinimag.2022.08.021_bb0130","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1007\/s00330-018-5737-z","article-title":"Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem\u00ae) examinations, including 3,209 performed on renally insufficient individuals","volume":"29","author":"Young","year":"2019","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.clinimag.2022.08.021_bb0135","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2214\/AJR.06.1094","article-title":"Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned","volume":"188","author":"Broome","year":"2007","journal-title":"AJR"},{"issue":"5","key":"10.1016\/j.clinimag.2022.08.021_bb0140","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/jmri.21135","article-title":"Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis","volume":"26","author":"Ersoy","year":"2007","journal-title":"J Magn Reson Imaging"},{"issue":"1042","key":"10.1016\/j.clinimag.2022.08.021_bb0145","doi-asserted-by":"crossref","first-page":"20140307","DOI":"10.1259\/bjr.20140307","article-title":"Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a research on adverse drug events and reports (RADAR) report","volume":"87","author":"Edwards","year":"2014","journal-title":"Br. J. Radiol."},{"issue":"6","key":"10.1016\/j.clinimag.2022.08.021_bb0155","article-title":"Correction: nephrogenic systemic fibrosis in Denmark \u2013 a nationwide investigation","volume":"9","author":"Elmhodt","year":"2014","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.clinimag.2022.08.021_bb0160","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/RLI.0000000000000072","article-title":"Progressive Increase of T1 Signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation","volume":"49","author":"Errante","year":"2014","journal-title":"Investig Radiol"},{"issue":"3","key":"10.1016\/j.clinimag.2022.08.021_bb0165","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1148\/radiol.13131669","article-title":"High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material","volume":"270","author":"Kanda","year":"2014","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.clinimag.2022.08.021_bb0170","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1148\/radiol.15150025","article-title":"Intracranial gadolinium deposition after contrast-enhanced MR imaging","volume":"275","author":"McDonald","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.clinimag.2022.08.021_bb0175","unstructured":"https:\/\/radiology.duke.edu\/wp-content\/uploads\/2016\/10\/Duke-Radiology-Contrast-Media-Guidelines-Final-10.13.16.pdf (Accessed on March 30, 2020)."},{"key":"10.1016\/j.clinimag.2022.08.021_bb0180","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204781s008lbl.pdf (Accessed on March 30, 2020)."}],"container-title":["Clinical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899707122002303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899707122002303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:50:24Z","timestamp":1760269824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0899707122002303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":35,"alternative-id":["S0899707122002303"],"URL":"https:\/\/doi.org\/10.1016\/j.clinimag.2022.08.021","relation":{},"ISSN":["0899-7071"],"issn-type":[{"value":"0899-7071","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile of Gadoterate meglumine on the renal function of patients with severe kidney disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinimag.2022.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}